NHS England to save £300m after patent expiry of most costly drug The NHS in England will save £300m from the patent expiry of adalimumab, the most costly drug used in NHS hospitals, which is double previous estimates, NHS England has announced.…
Low clinician engagement and patient resistance main barriers to biosimilars uptake say CCGs Lack of clinician engagement, patient resistance, and safety concerns were among the main barriers to biosimilars uptake according to a survey of 134 clinical commissioning groups by NHS England.…
Most expensive NHS drug comes off patent The health service’s most expensive drug has come off patent, which could save it at least £150 million per year by 2021.…
Pharmacists have good understanding of biosimilars but concerns over switching, study results show UK pharmacists have a high level of understanding of biosimilars but have concerns about the safety and efficacy of switching patients to the drugs, research has shown.…
Ten things pharmacists should know about biologics and biosimilars As healthcare professionals prepare for blockbuster biologic Humira to come off patent on 16 October 2018, we highlight what pharmacists need to know about switching from originator biologics to biosimilars in order to get the best value from these medicines.…
Proposals to include biologics in price controls could threaten NHS savings, says biosimilars head Government proposals to include all biologics within the scope of price-controlled health service medicines could impact patient benefit and threaten NHS England’s savings target, the director general of the British Generic Manufacturers Association and the British Biosimilars Association has …
Switching to biosimilar and generic medicines saved the NHS over £300m in a year NHS England saved £324m in 2017/2018 by switching from using ten “expensive” medicines to “better value and equally effective” alternatives, mainly generic and biosimilar medicines, NHS Improvement has revealed.…
EMA recommends six medicines for approval The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended six medicines for approval, including two biosimilars and one orphan medicine.…
EMA recommends seven new medicines for approval Included in the recommendations by the Committee for Medicinal Products for Human Use were one biosimilar and one orphan medicine…
